MIRA INFORM REPORT

 

 

Report Date :

29.06.2013

 

IDENTIFICATION DETAILS

 

Name :

TOCHIMOTO TENKAIDO CO LTD 

 

 

Registered Office :

5-10-3 Fukushima Fukushimaku Osaka

 

 

Country :

Japan

 

 

Financials (as on) :

31.05.2013

 

 

Date of Incorporation :

December 1949

 

 

Com. Reg. No.:

1200-01-035810 (Osaka-Fukushimaku)

 

 

Legal Form :

Limited Company

 

 

Line of Business :

Manufacturer of Chinese medicines, herbal medicines

 

 

No. of Employees :

160

 

 

RATING & COMMENTS

 

MIRA’s Rating :

Ba

 

RATING

STATUS

PROPOSED CREDIT LINE

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

Satisfactory

Company name                     TOCHIMOTO TENKAIDO CO LTD

 

REGD NAME:                           KK Tochimoto Tenkaido

 

MAIN OFFICE:                          3-21 Suehirocho Kitaku Osaka 530-0053

      Tel: 06-6312-8425     Fax: 06-6311-6036

*.. Registered at: 5-10-3 Fukushima Fukushimaku Osaka

 

URL:                             http://www.tochimoto.co.jp

E-mail Address:                       info@tochimoto.co.jp      

 

ACTIVITIES:                             Mfg of Chinese medicines, herbal medicines

 

BRANCHES:                             Tokyo, Fukuoka

 

FACTORIES:                            Umehara

 

OFFICER(S):                             KAZUO TOCHIMOTO, PRES      Toko Yo, v pres

Fumio Tochimoto, s/mgn dir      Sadako Tochimoto, dir 

                                                Daisuke Tochimoto, dir              Kyosuke Tochimoto, dir

 

Yen Amount:                             In million Yen, unless otherwise stated

 

SUMMARY:                              FINANCES        FAIR                             A/SALES          Yen 4,200 M

                                                PAYMENTS      No  Complaints         CAPITAL           Yen 80 M

                                                TREND             STEADY                       WORTH            Yen 852 M

                                                STARTED         1949                             EMPLOYES      160

 

COMMENT:                              MFR OF CHINESE MEDICNES. 

 

 FINANCIAL SITUATION CONSIDERED FAIR AND GOOD FOR ORDINARY   BUSINESS ENGAGEMENTS

 

                                                MAX CREDIT LIMIT: YEN 76.2 MILLION, 30 DAYS NORMAL TERMS

 

HIGHLIGHTS:

           

The subject company was established by father of Kazuo Tochimoto for importing Chinese medicines from China.  This is a specialized mfr of Chinese medicines and herbal medicines centrally.  Materials & ingredients are imported from China, India, other.

 

 

FINANCIAL INFORMATION:

 

Financials are only partially disclosed as is the case with family-based companies.

 

The sales volume for May/2012 fiscal term is estimated amounted to Yen 4,200 million, a 5% up from Yen 4,000 million in the previous term.  Herbal medicines, including herbal teas, were in much demand.  The net profit is believed posted at Yen 40 million, similarly in the previous term.  Financials for this term are not precisely disclosed and the figures have been collected from outside sources.  .

 

For the term that ended May 2013 the net profit was projected at Yen 42 million, on a 4% rise in turnover, to Yen 4,350 million.  Final results are yet to be released. 

           

The financial situation is considered FAIR and good for ORDINARY business engagements.  Max credit limit is estimated at Yen 76.2 million, on 30 days normal terms. 

 

 

REGISTRATION

 

Date Registered:       Dec 1949

Regd No.:                 1200-01-035810 (Osaka-Fukushimaku)

Legal Status:    　Limited Company (Kabushiki Kaisha)

Authorized:      　640,000 shares

Issued:             　160,000 shares

Sum:                　Yen 80 million

Major shareholders (%): Kazuo Tochimoto and families (--100)

No. of shareholders: 7

 

Nothing detrimental is known as to the commercial morality of executives.

 

 

OPERATION:

 

Activities: Manufactures Chinese/herbal medicines, herbal teas, health foods, other (--100%)

 

Clients: [Pharmaceutical firms, wholesalers] Kotaro Pharmaceutical Co, Tochimeien Hompo, JBS Pharmaceuticals, other

            No. of accounts: 300

            Domestic areas of activities: Nationwide

 

Suppliers: [Mfrs, wholesalers] Nomura Trading, Kamei Pharmaceuticals, other.

Imports from China, India, other.

 

Payment record: No  Complaints 

 

Location: Business area in Osaka.  Office premises at the caption address are leased and maintained satisfactorily.

 

Bank References:

MUFG (Dojima)

SMBC (Umeda)

Relations: Satisfactory

 

FINANCES

(In Million Yen)

 

Terms Ending:

　

31/05/2013

31/05/2012

31/05/2011

31/05/2010

Annual Sales

　

4,350

4,200

4,000

3,900

Recur. Profit

　

..

..

..

..

Net Profit

　

42

40

40

39

Total Assets

　

　

N/A

N/A

N/A

Net Worth

　

　

852

812

773

Capital, Paid-Up

　

　

80

80

80

Div.P.Share(¥)

　

　

0.00

0.00

0.00

<Analytical Data>

(%)

(%)

(%)

(%)

    S.Growth Rate

3.57

5.00

2.56

18.18

    Current Ratio

 

 

..

..

..

    N.Worth Ratio

 

..

..

..

    N.Profit/Sales

0.97

0.95

1.00

1.00

 

Notes: Financials are only partially disclosed in rounded-off numbers.

Forecast (or estimated) figures for the 31/05/2013 fiscal term. 

 

 

 

RATING EXPLANATIONS

 

RATING

STATUS

 

 

PROPOSED CREDIT LINE

>86

Aaa

Possesses an extremely sound financial base with the strongest capability for timely payment of interest and principal sums

 

Unlimited

71-85

Aa

Possesses adequate working capital. No caution needed for credit transaction. It has above average (strong) capability for payment of interest and principal sums

 

Large

56-70

A

Financial & operational base are regarded healthy. General unfavourable factors will not cause fatal effect. Satisfactory capability for payment of interest and principal sums

 

Fairly Large

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

 

Satisfactory

26-40

B

Capability to overcome financial difficulties seems comparatively below average.

 

Small

11-25

Ca

Adverse factors are apparent. Repayment of interest and principal sums in default or expected to be in default upon maturity

 

Limited with full security

<10

C

Absolute credit risk exists. Caution needed to be exercised

 

 

Credit not recommended

----

NB

New Business

----

 

This score serves as a reference to assess SC’s credit risk and to set the amount of credit to be extended. It is calculated from a composite of weighted scores obtained from each of the major sections of this report. The assessed factors and their relative weights (as indicated through %) are as follows:

 

Financial condition (40%)            Ownership background (20%)                  Payment record (10%)

Credit history (10%)                   Market trend (10%)                                Operational size (10%)

PRIVATE & CONFIDENTIAL : This information is provided to you at your request, you having employed MIPL for such purpose. You will use the information as aid only in determining the propriety of giving credit and generally as an aid to your business and for no other purpose. You will hold the information in strict confidence, and shall not reveal it or make it known to the subject persons, firms or corporations or to any other. MIPL does not warrant the correctness of the information as you hold it free of any liability whatsoever. You will be liable to and indemnify MIPL for any loss, damage or expense, occasioned by your breach or non observance of any one, or more of these conditions

This report is issued at your request without any risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL) or its officials.